 Connection
Bryan Haugen to Thiazolidinediones
This is a "connection" page, showing publications Bryan Haugen has written about Thiazolidinediones.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.691 |
|
|
|
-
Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer. 2009 Mar 06; 8:16.
Score: 0.288
-
Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther. 2004 Aug; 3(8):1011-20.
Score: 0.209
-
Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 04 01; 103(4):1277-1281.
Score: 0.135
-
Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13; 25(16):2304-17.
Score: 0.059
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|